Eksozomlar ve Kanserdeki Rolleri

Yıl 2018, Cilt: 45 Sayı: 2, 209 - 217, 15.06.2018

Süreyya Bozkurt

https://doi.org/10.5798/dicletip.424986

Cited By: 1

Öz

Eksozomlar, vücutta bulunan hücrelerin neredeyse tamamı
tarafından salgılanan, 40-100 nanometre (nm) çapında ve çift fosfolipid tabaka
ile çevrili ekstrasellüler veziküllerdir. İçlerinde proteinler, lipitler, çok
çeşitli RNA molekülleri ve DNA fragmenleri gibi birçok biyomolekül taşırlar. Bu
biyomoleküller vasıtasıyla, alıcı hücrelerde gen ifadelerini düzenleyerek,
immün regülasyon, hücre farklılaşması, hücreler arası haberleşme, hücre göçü
gibi birçok biyolojik fonksiyonda rol alırlar. Tümör kökenli eksozomlar ise
içlerinde taşıdıkları biyomoleküller vasıtasıyla kanserin gelişimi ve
yayılımına yardım etmek için lokal ve sistemik çevreyi düzenlerler. Eksozom
içeriklerinin kanserin tanısında ve hastalık seyrinin izlenmesinde biyobelirteç
olarak kullanım potansiyellerini araştıran çalışmalar hızla artmaktadır. Ayrıca
son yıllarda kanser tedavisinde eksozomların hedeflendiği ya da kullanıldığı
yaklaşımlar da bulunmaktadır. Bu derlemenin amacı eksozomların yapısının,
kanser gelişimindeki ve metastazdaki rollerinin ve kanser tedavisindeki
kullanım potansiyellerinin ortaya konmasıdır.

Anahtar Kelimeler

Eksozomlar, kanser, tümör metastazı

Kaynakça

• 1. Trams EG, Lauter CJ, Salem Jr N, Heine U. Exfoliation of membrane ectoenzymes in the form of micro-vesicles. Biochim Biophys Acta. 1981; 645: 63-70.
• 2. Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J Biol Chem. 1987; 262: 9412-20.
• 3. Xu W, Yang Z, Lu N. From pathogenesis to clinical application: insights into exosomes as transfer vectors in cancer. J Exp Clin Cancer Res. 2016; 35: 156-168.
• 4. Tkach M, Thery C. Communication by extracellular vesicles: Where we are and where we need to go. Cell. 2016; 164: 1226–32.
• 5. Yuana Y, Sturk A, Nieuwland R. Extracellular vesicles in physiological and pathological conditions. Blood Rev. 2013; 27: 31-9.
• 6. Staubach S, Razawi H, Hanisch FG. Proteomics of MUC1-containing lipid rafts from plasma membranes and exosomes of human breast carcinoma cells MCF-7. Proteomics. 2009; 9: 2820-35.
• 7. Yim N, Ryu SW, Choi K, et al. Exosome engineering for efficient intracellular delivery of soluble proteins using optically reversible protein-protein interaction module. Nat Commun. 2016; 7: 12277-86.
• 8. Subra C, Laulagnier K, Perret B, et al. Exosome lipidomics unravels lipid sorting at the level of multivesicular bodies. Biochimie. 2007; 89: 205–12.
• 9. Wang J, Sun X, Zhao J, et al. Exosomes: A Novel Strategy for Treatment and Prevention of Diseases. Front Pharmacol. 2017; 8: 300-313.
• 10. Whiteside TL. Tumor- Derived Exosomes and Their Role in Cancer Progression. Adv Clin Chem. 2016; 74: 103-41.
• 11. Henne WM, Buchkovich NJ, Emr SD. The ESCRT pathway. Dev Cell. 2011; 21: 77–91.
• 12. Yanez-Mo M, Barreiro O, Gordon-Alonso M, Sala-Valdes M, Sanchez-Madrid F. Tetraspanin-enriched microdomains: a functional unit in cell plasma membranes. Trends Cell Biol. 2009; 19: 434–46.
• 13. Verweij FJ, van Eijndhoven MA, Hopmans ES, et al. LMP1 association with CD63 in endosomes and secretion via exosomes limits constitutive NF-kappaB activation. EMBO J. 2011; 30: 2115–29.
• 14. Villarroya-Beltri C, Baixauli F, Gutiérrez-Vázquez C, Sánchez-Madrid F, Mittelbrunn M. Sorting it out: regulation of exosome loading. Semin Cancer Biol. 2014; 28: 3-13.
• 15. Kahlert C, Kalluri R. Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med (Berl) 2013; 91: 431-7.
• 16. Wang Z, Chen JQ, Liu JL, Tian L. Exosomes in tumor microenvironment: novel transporters and biomarkers. J Transl Med. 2016; 14: 297-306.
• 17. Wang M, Ji S, Shao G, et al. Effect of exosome biomarkers for diagnosis and prognosis of breast cancer patients. Clin Transl Oncol 2017; doi: 10.1007/s12094-017-1805-0.
• 18. Neviani P, Fabbri M. Exosomic microRNAs in the Tumor Microenvironment. Front Med (Lausanne). 2015; 2: 47-53.
• 19. King HW, Michael MZ, Gleadle JM. Hypoxic enhancement of exosome release by breast cancer cells. BMC Cancer. 2012; 12: 421-31.
• 20. Li W, Li C, Zhou T, et al. Role of exosomal proteins in cancer diagnosis. Mol Cancer. 2017; 16: 145.
• 21. Dorayappan KDP, Wallbillich JJ, Cohn DE, Selvendiran K. The biological significance and clinical applications of exosomes in ovarian cancer. Gynecol Oncol. 2016; 142: 199-205.
• 22. Zhang HG, Grizzle WE. Exosomes: a novel pathway of local and distant intercellular communication that facilitates the growth and metastasis of neoplastic lesions, Am J Pathol. 2014; 184: 28-41.
• 23. Lynch C, Panagopoulou M, Gregory CD. Extracellular Vesicles Arising from Apoptotic Cells in Tumors: Roles in Cancer Pathogenesis and Potential Clinical Applications. Front Immunol. 2017; 8: 1174.
• 24. Syn N, Wang L, Sethi G, Thiery JP, Goh BC. Exosome-Mediated Metastasis: From Epithelial-Mesenchymal Transition to Escape from Immunosurveillance. Trends Pharmacol Sci. 2016 Jul; 37:606-17.
• 25. Schuler PJ, Saze Z, Hong CS, et al. Human CD4(+) CD39(+) regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73(+) exosomes or CD73(+) cells, Clin. Exp. Immunol. 2014; 177: 531-43.
• 26. Muller-Haegele S, Muller L, Whiteside TL. Immunoregulatory activity of adenosine and its role in human cancer progression. Expert Rev Clin Immunol. 2014; 10: 897-914.
• 27. Yin J, Yan X, Yao, Y, et al. Secretion of annexin, A3 from ovarian cancer cells and its association with platinum resistance in ovarian cancer patients, J.Cell Mol.Med. 2012; 16: 337-48.
• 28. Amorim M, Fernandes G, Oliveira P, Martins-de-Souza D, Dias-Netoand E, Nunes D. The overexpression of a single oncogene (ERBB2/HER2) alters the proteomic landscape of extracellular vesicles. Proteomics. 2014; 14: 1472-9.
• 29. Mao L, Li J, Chen WX, et al. Exosomes decrease sensitivity of breast cancer cells to adriamycin by delivering microRNAs. Tumor Biol. 2016; 37: 5247-56.
• 30. Fujita Y, Yoshioka Y, Ochiya T. Extracellular vesicle transfer of cancer pathogenic components. Cancer Sci. 2016; 107: 385-90.
• 31. Duijvesz D, Burnum-Johnson KE, Gritsenko MA, et al. Proteomic profiling of exosomes leads to the identification of novel biomarkers for prostate cancer. PLoS One. 2013; 8: e82589.
• 32. Bryant RJ, Pawlowski T, Catto JW, et al. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer. 2012; 106: 768-74.
• 33. Lee TJ, Yoo JY, Shu D, et al. RNA Nanoparticle-Based Targeted Therapy for Glioblastoma through Inhibition of Oncogenic miR-21. Mol Ther. 2017; 25: 1544-55.
• 34. Graner MW, Alzate O, Dechkovskaia AM, et al. Proteomic and immunologic analyses of brain tumor exosomes. FASEB J. 2009; 23: 1541–57.
• 35. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem. 2010; 285: 17442–52.
• 36. Chalmin F, Ladoire S, Mignot G, et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest. 2010; 120: 457–71.